<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6303">
  <stage>Registered</stage>
  <submitdate>18/10/2016</submitdate>
  <approvaldate>18/10/2016</approvaldate>
  <nctid>NCT02942290</nctid>
  <trial_identification>
    <studytitle>A Study Evaluating Venetoclax in Combination With Azacitidine in Subjects With Treatment-Na誰ve Higher-Risk Myelodysplastic Syndromes (MDS)</studytitle>
    <scientifictitle>A Phase 1b Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination With Azacitidine in Subjects With Treatment-Na誰ve Higher-Risk Myelodysplastic Syndromes (MDS)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-001657-41</secondaryid>
    <secondaryid>M15-531</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Treatment-Na誰ve Higher-Risk Myelodysplastic Syndromes (MDS)</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Venetoclax
Treatment: drugs - Azacitidine

Experimental: Venetoclax + Azacitidine - 


Treatment: drugs: Venetoclax
Tablet; oral; Administered on Days 1-14 of 28 day cycle

Treatment: drugs: Azacitidine
Powder for injection; taken subcutaneously or intravenous (IV); Administered on Days 1-7 of 28 days cycle or Days 1-5 of Week 1 &amp; Days 1-2 of Week 2 of 28 day cycle.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Recommended Phase 2 dose (RPTD) and dosing schedule of venetoclax in combination with azacitidine</outcome>
      <timepoint>Measured from Day 1 until Day 28 per dose level.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Cmax of venetoclax - Maximum plasma concentration (Cmax) of venetoclax</outcome>
      <timepoint>Up to 32 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Tmax of venetoclax - Time to Cmax (peak time, Tmax) of venetoclax</outcome>
      <timepoint>Up to 32 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>AUCt for venetoclax - Area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt) for venetoclax</outcome>
      <timepoint>Up to 32 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>AUC[0-24] for venetoclax - AUC over a 24-hour dose interval (AUC[0-24]) for venetoclax</outcome>
      <timepoint>Up to 32 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Cmax for azacitidine - Maximum plasma concentration (Cmax) of azacitdine</outcome>
      <timepoint>Up to 32 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Tmax for azacitidine - Time to Cmax (peak time, Tmax) of azacitidine</outcome>
      <timepoint>Up to 32 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Half-life (t[1/2]) for azacitidine - Terminal elimination half-life (t[1/2]) for azacitidine</outcome>
      <timepoint>Up to 32 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>AUCt for azacitidine - Area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt) for azacitidine</outcome>
      <timepoint>Up to 32 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>AUC[0 to infinity] for azacitidine - Area under the plasma concentration-time curve from Time 0 to infinite time.</outcome>
      <timepoint>Up to 32 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Clearance (CL) for azacitidine</outcome>
      <timepoint>Up to 32 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Response Rate (ORR) - ORR (equals the sum of rates of complete remission [CR] + partial remission [PR]) of venetoclax in combination with azacitidine.</outcome>
      <timepoint>Measured from Day 1 until until the lack of treatment benefit or unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Complete Response (CR) rate - Complete response rate will be defined as the proportion of subjects who achieved a complete response per the International Working Group (IWG) criteria for Myelodysplastic Syndromes (MDS).</outcome>
      <timepoint>Measured from Day 1 until the lack of treatment benefit or unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hematologic Improvement (HI) rate - Percentages of participants with HI (erythroid/platelet/neutrophil responses)</outcome>
      <timepoint>Measured from Day 1 until the lack of treatment benefit or unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of red blood cell (RBC) transfusion independence - Percentages of participants who become RBC transfusion-independent</outcome>
      <timepoint>Measured from Day 1 until the lack of treatment benefit or unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of platelet (PLT) transfusion independence - Percentages of participants who become platelet transfusion-independent</outcome>
      <timepoint>Measured from Day 1 until the lack of treatment benefit or unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of cytogenetic response - Percentages of participants with cytogenetic response</outcome>
      <timepoint>Measured from Screening until the lack of treatment benefit or unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of bone marrow blast response - Percentages of participants with a bone marrow blast response</outcome>
      <timepoint>Measured from Screening until evidence of MDS progression, the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to transformation to acute myelogenous leukemia (AML)</outcome>
      <timepoint>Measured from the date of first dose of study drug to the date of documented AML transformation, defined as a bone marrow blast count greater than or equal to 20% independent of baseline bone marrow count.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response (DOR)</outcome>
      <timepoint>Measured from the date of first response (CR or PR) to the earliest documentation of progressive disease (PD).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS)</outcome>
      <timepoint>Measured from the date of first dose of study drug to the date of death.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-Free Survival (PFS)</outcome>
      <timepoint>Measured from the date of first dose of study drug to the date of earliest disease progression or death.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to next treatment (TTNT)</outcome>
      <timepoint>Measured from the first dose of study drug to start of new non-protocol specified MDS therapy.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Event-Free Survival (EFS)</outcome>
      <timepoint>Measured from the date of the first dose of study drug to the date of earliest disease progression, death, or initiation of new non-protocol-specified MDS therapy without documented progression.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Participant must have documented diagnosis of de novo MDS with:

          -  International Prognostic Scoring System (IPSS) risk categories Int-2 or High (IPSS
             overall score = 1.5) and

          -  Presence of greater than or equal to 5% and less than 20% bone marrow blasts per bone
             marrow

               -  Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal
                  to 2.

               -  Participant is not a candidate to undergo intensive chemotherapy or allogeneic
                  hematopoietic stem cell transplantation (HSCT).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- Participant has received prior therapy for MDS. (Prior supportive
        care in form of transfusions or growth factors, etc., is not considered prior therapy.)

          -  Participant has received prior therapy with a BH3 mimetic.

          -  Participant has a diagnosis other than previously untreated de novo MDS with IPSS risk
             categories Int-2 or High, including:

               -  MDS with IPSS risk categories Low or Int-1 (overall IPSS score &lt; 1.5)

               -  Therapy-related MDS (t-MDS)

               -  MDS evolving from a pre-existing myeloproliferative neoplasm (MPN)

               -  MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic
                  myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML) and
                  unclassifiable MDS/MPN

          -  Participant has received allogeneic HSCT or solid organ transplantation.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>13/03/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>44</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>12/12/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Princess Alexandra Hospital /ID# 154990 - Brisbane</hospital>
    <hospital>Concord Hospital /ID# 154958 - Concord</hospital>
    <hospital>Austin Hospital /ID# 154955 - Heidelberg</hospital>
    <hospital>St. George Hospital /ID# 154954 - Kogarah</hospital>
    <hospital>Alfred Health /ID# 154956 - Prahran</hospital>
    <hospital>Calvary Mater Newcastle /ID# 154957 - Warratah</hospital>
    <postcode>4102 - Brisbane</postcode>
    <postcode>2139 - Concord</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>2217 - Kogarah</postcode>
    <postcode>3181 - Prahran</postcode>
    <postcode>2298 - Warratah</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Montreal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Halle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Koeln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mannheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Aberdeen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newcastle Upon Tyne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Norwich</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Genentech, Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating
      venetoclax in combination with azacitidine in subjects with treatment-na誰ve higher-risk MDS
      comprising a dose-escalation portion and a safety expansion cohort.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02942290</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Thomas Jahn, MD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>AbbVie_Call Center</name>
      <address />
      <phone>847-283-8955</phone>
      <fax />
      <email>abbvieclinicaltrials@abbvie.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>